Business ❯ Pharmaceuticals

Vaccine Development

Moderna Clinical Trials Novavax Market Impact Research and Development Corporate Governance Market Reactions AstraZeneca Collaboration Agreements mRNA Technology Moderna Inc. Funding Market Competition COVID-19 Vaccines COVID-19 Vaccine Pricing Strategies Contracts Covid-19 Vaccines Corporate Deals Research Funding Cancer Vaccine Regulatory Affairs Market Response Seattle-based Manufacturing Investment Decisions Manufacturing Agreements Market Performance Manufacturers Valneva Valneva SE Technology Transfer Corporate Communication Pfizer

Pfizer and BioNTech Halt U.S. COVID Vaccine Trial for 50–64-Year-Olds Over Slow Enrollment

Tougher FDA rules are squeezing efforts to test shots in healthy adults 50 to 64.

CEPI Puts Up to $54.3 Million Behind Moderna’s H5 mRNA Bird Flu Vaccine for Phase 3

FDA Suspends Valneva’s Ixchiq Chikungunya Vaccine Over Safety Reports

Moderna’s mRNA-1010 Flu Vaccine Outperforms Standard Shot and Advances Toward Approval

FDA Expands Moderna RSV Vaccine to Adults 18–59 at Risk

FDA Approves Moderna’s mNEXSPIKE for Seniors and High-Risk Adults as CDC Drops Recommendations for Healthy Children and Pregnant Women

HHS Withdraws $766 Million From Moderna’s Bird Flu Vaccine Program

Moderna Withdraws Flu-COVID Vaccine Application After FDA Requests More Data

FDA Grants Limited Approval to Novavax’s COVID-19 Vaccine